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 Urinary tract infection (UTI) — including 
asymptomatic bacteriuria, cystitis, and 
pyelonephritis — is the most common 
form of bacterial infection following renal 
transplantation. 1 For example, in the 
recent ELITE-Symphony trial, 2 approxi-
mately 25 % of patients had symptomatic 
UTIs during the fi rst year aft er transplan-
tation regardless of the immunosuppres-
sion protocol used. However, the fact that 
posttransplant UTIs are oft en asympto-
matic suggests that the magnitude and 
implications of this problem are larger 
than is generally appreciated. Th e study by 
Fiorante  et al. 3 in this issue of  Kidney 
International provides direct evidence of 
this, the authors having shown that bacte-
riuria and / or cystitis aff ects at least 50 % of 
transplant recipients and is oft en recur-
rent. It is diffi  cult to assess the incidence 
of pyelonephritis aft er kidney transplanta-
tion because these infections may either 
be asymptomatic or have an atypical clin-
ical presentation, as discussed below. 
Therefore the diagnosis of allograft 
pyelonephritis on clinical grounds may be 
of questionable accuracy. 
 UTIs aft er kidney transplantation have 
important implications. Th ey may be 
associated with bacteremia and may 
require hospitalization. Th e recurrent 
nature of the problem necessitates the 
use of multiple courses of antibiotic 
therapy, which are not only costly but 
can result in bacterial resistance and 
contribute to erratic levels of immuno-
suppression. Repeated infections may 
also lead to graft inflammation and 
fi brosis 4 — an observation supported by 
the current study of Fiorante  et al. 3 A 
previous large retrospective review 
found that UTIs occurring more than 6 
months posttransplant were associated 
with an increased risk of graft  loss and 
even death. 5 Likewise, allograft  pyelone-
phritis has been associated, at least in 
some studies, with reduced allograft 
function 1,6 and may lead to graft  loss. 7 
However, it is possible that pyelonephri-
tis is more common than we clinically 
suspect; thus the impact of allograft 
infection on graft  function and survival 
may be underestimated. Th is postulate 
is supported by a recent report of 40 
cases of allograft  pyelonephritis diag-
nosed by either protocol or clinical 
biopsy (abstract presented at the 2009 
annual meeting of the American Society 
of Nephrology). In most of these cases 
the disease was not suspected clinically. 
Interestingly, many of the cases of 
pyelonephritis were associated with pre-
ceding episodes of  ‘ uncomplicated ’ UTI 
that had been treated. Despite the high 
incidence and detrimental impact of 
posttransplant UTIs, specifi c guidelines 
regarding screening and management 
are lacking. Current guidelines simply 
recommend that kidney transplant 
recipients receive posttransplant UTI 
prophylaxis with trimethoprim – sulfa-
methoxazole and that patients with allo-
graft  pyelonephritis receive intravenous 
antibiotics in the hospital. 8 
 Many factors are thought to contribute 
to the high incidence of posttransplant 
UTI ( Figure 1 ). Some exist prior to trans-
plant, including female sex, diabetes mel-
litus, and underlying urinary tract 
abnormalities. In addition, peritransplant 
factors are important and are oft en related 
to instrumentation of the urinary tract, 
including ureteral stenting and prolonged 
urinary catheterization. Of interest are 
some studies showing that recipients of 
kidneys from deceased donors may also 
be at higher risk of UTIs than recipients of 
living-donor graft s. We postulate that this 
association may be related to the higher 
incidence of delayed graft  function aft er 
transplantation with a deceased-donor 
organ and / or to bladder dysfunction aft er 
a prolonged time on dialysis. Th e impor-
tance of the latter factor, in our opinion, 
cannot be overestimated. It is indeed a 
challenge to evaluate the functional capac-
ity of the urinary tract in kidney transplant 
candidates who have been on dialysis for 
prolonged periods of time because these 
patients produce very little urine. Th ey 
frequently have bladders with very small 
capacities and significant dysfunction. 
Furthermore, signifi cant bladder outlet 
obstruction, particularly in males, may not 
be appreciated until aft er the transplant, 
leading to prolonged instrumentation and 
an increased risk of UTI. 
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 Additional risk factors contributing to 
UTI posttransplant include immunosup-
pression and graft  dysfunction or rejection. 9 
It is noteworthy that there is no clear asso-
ciation between the risk of UTI and dose or 
type of maintenance immunosuppression. 2 
In addition to these factors, in our clinical 
practice we have been impressed with the 
frequent association between repeated epi-
sodes of UTI and diarrhea, a common and 
oft en troublesome posttransplant compli-
cation. 2 This association has not been 
described in previous studies, but it is use-
ful to recognize because resolution of 
recurrent UTIs in these patients requires 
treatment of the diarrhea. Posttransplant 
UTIs are most frequent during the fi rst year 
aft er surgery, 1,3 suggesting that periopera-
tive factors and perhaps the higher levels of 
immunosuppression used during the fi rst 
year aft er transplantation are major con-
tributors to risk. 
 In this issue of  Kidney International , 
Fiorante and colleagues report a single-
center retrospective study describing the 
results of a protocol involving surveil-
lance for asymptomatic bacteriuria (AB) 
in kidney transplant recipients. 3 It should 
be noted that this center ’ s protocol 
includes routine antimicrobial treatment 
of AB — a feature that limits the authors ’ 
ability to assess the implications of AB 
when left  untreated. Still, this study pro-
vides important and useful information 
about UTI aft er transplantation. First, 
the authors found that 51 % of patients 
developed at least one episode of AB dur-
ing their first 3 posttransplant years. 
Notably, this is a signifi cantly higher inci-
dence than that described for sympto-
matic UTI, 7 illustrating once again that 
UTIs are a problem of larger magnitude 
than is commonly appreciated. It is strik-
ing to note that although the authors 
searched systematically for bacteriuria 
and treated most episodes of AB, symp-
tomatic cystitis and clinically diagnosed 
pyelonephritis still occurred in 12 % and 
13 % of patients, respectively. Th e authors 
identifi ed  ‘ double renal transplants ’ (that 
is, transplantation of two kidneys from 
the same donor  en bloc ) as a risk factor 
for UTI. This association is perhaps 
expected, given the more complex uri-
nary tract anatomy in these instances. 
Th e association described in this manu-
script between the pretransplant diagno-
sis of  ‘ glomerulonephritis ’ and UTI is less 
intuitive and deserves reexamination in 
future studies. 
 Unfortunately, the study by Fiorante 
 et al. 3 does not answer the question of 
whether surveillance and treatment of 
AB aft er kidney transplantation are clin-
ically useful exercises because most of 
their patients with AB had received anti-
microbial treatment. Indeed, the utility 
of UTI surveillance programs is not a 
foregone conclusion. Thus, although 
these protocols are useful in pregnancy 
and in patients undergoing urologic pro-
cedures, they do not appear to be useful 
in patients with diabetes. 10 In our opin-
ion, the lack of association between 
treated AB and graft  function, proteinu-
ria, or graft  survival in the present study 3 
should not be interpreted as indicating 
that AB is clinically irrelevant. It is inter-
esting that, despite aggressive therapy, 
repeated episodes of AB were still associ-
ated with an increased risk of pyelone-
phritis, suggesting that either the 
antimicrobial therapy was ineff ective or 
additional risk factors — perhaps related 
to anatomy or instrumentation — played 
a role. In that respect, it appears that 
30 % of the patients with AB did not 
receive antimicrobial treatment. How-
ever, the authors did not provide infor-
mation about the outcome of this 
subgroup of patients. Th e retrospective 
nature of the Fiorante study indeed 
makes causality very diffi  cult to deter-
mine. It should be noted that the study 
cohort included few patient with 
diabetes (and despite this the incidence 
of AB was very high!) and no recipients 
of living-donor kidney transplants. 
 Notwithstanding the limitations noted 
above, Fiorante  et al .  should be 
applauded for undertaking this study, 
for providing important new informa-
tion about UTIs aft er kidney transplan-
tation, and for pointing out the general 
lack of knowledge regarding this impor-
tant topic. Clinical studies in kidney 
transplant recipients generally focus on 
major posttransplant events such as 
acute rejection, immunosuppression, 
and graft  or patient survival. However, 
the practice of kidney transplantation 
has changed dramatically in recent years, 
with a marked reduction in the risk of 
acute rejection and improvements in 
antibiotics and immunosuppressive 
drugs. As the risk of graft  injury from 
processes such as acute rejection 
declines, the importance of allograft 
injury from other mechanisms, previ-
ously considered less important, 
increases in relevance. In that respect, 
infections — particularly those aff ecting 
the urinary tract — are well deserving of 
investigation. Improvements in the pre-
vention and care of these infections will 
probably also improve patient satisfac-
tion, reduce hospitalizations and costs, 
and in some patients result in improved 
graft  function and survival. Indeed, these 
are loft y goals. 
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 Th e hemolytic uremic syndrome (HUS, 
MIM 235,400) is a condition character-
ized by thrombocytopenia, microangio-
pathic hemolytic anemia, and acute renal 
failure due to glomerular thrombotic 
microangiopathy. Th e majority of HUS 
episodes are triggered by  Escherichia coli 
0157:H7 infection. However, a minority 
of cases are not associated with infection; 
this form, termed atypical HUS (aHUS), 
has the poorest long-term prognosis. Dur-
ing the last decade there has been dra-
matic progress in understanding the 
pathogenesis of aHUS, particularly 
through the study of familial forms. 
Approximately half of all aHUS cases have 
been associated with mutations and / or 
polymorphisms in genes encoding pro-
teins of the complement system. Muta-
tions in the regulatory proteins of this 
system resulted in  ‘ loss of function, ’ 
whereas mutations in genes encoding 
complement activation proteins resulted 
in  ‘ gain of function. ’ 1 Mutations in throm-
bomodulin, an endothelial glycoprotein, 
have recently been associated with aHUS. 2 
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These mutations were associated with 
impaired complement regulation  in vitro . 
Together with other lines of evidence, 
aHUS is now viewed as a disorder in 
which there is defective complement reg-
ulation ( Figure 1 ). 
 In many individuals, both genetic sus-
ceptibility factors and an environmental 
insult are required for the syndrome to 
develop. For example, many environmen-
tal factors — such as infection, pregnancy, 
and drugs — have been reported to trigger 
episodes of aHUS. 1 Family studies have 
clearly shown that multiple genetic risk 
factors are generally required for the con-
dition to become manifest. For example, 
in one pedigree in which there were three 
independently segregating aHUS-associ-
ated risk factors, the syndrome developed 
only among individuals possessing all 
three risk factors. 3 
 Th e investigation of individuals with 
aHUS for genetic susceptibility factors 
has become increasingly complex 
because both the number and nature of 
reported genetic defects has expanded. 
Th e diagnostic workup of aff ected indi-
viduals is summarized in  Figure 2 . Exon 
sequencing to screen for mutations in 
complement regulatory ( CFH, CFI, and 
 MCP (membrane cofactor protein, also 
known as CD46)) and activation ( C3, 
CFB ) genes and the thrombomodulin 
gene ( THRB ) is relatively straightfor-
ward. However, signifi cant complexity 
arises within the  CFH gene family. Com-
plement factor H (CFH) is the major 
regulator of the complement alternative 
pathway, and mutations in the  CFH gene 
are among the most frequent alterations 
detected in the majority of aHUS 
cohorts. Th e  CFH gene is located in the 
 ‘ regulators of complement activation ’ 
(RCA) gene cluster on chromosome 
1q32. 4 Th e gene encodes the CFH pro-
tein, an abundant plasma protein com-
prising 20 globular domains termed 
short consensus repeat (SCR) domains. 
In addition, through alternative splicing, 
the  CFH gene also encodes a smaller 
protein consisting of only seven SCR 
domains, termed factor H – like 1 (FHL-1). 
With the exception of the C-terminal 
four amino acids, the FHL-1 protein 
sequence is identical to the fi rst seven 
SCR domains of CFH. In close proximity 
